Choose your country to see the products for your location

SALSA MLPA Probemix P138 SLC2A1-STXBP1

GLUT1 deficiency syndrome; STXBP1 encephalopathy with epilepsy; Ohtahara syndrome

Region: SLC2A1 1p34.2; STXBP1 9q34.1

MLPA | CE IL
Intended use: The SALSA MLPA probemix P138-C1 SLC2A1-STXBP1 is an in vitro diagnostic (IVD)1 or research use only (RUO) assay for (1) the detection of deletions or duplications in the SLC2A1 gene in order to confirm a potential cause and clinical diagnosis for Glucose transporter type 1 deficiency syndrome (GLUT1 DS), and (2) the detection of deletions or duplications in the human STXBP1 gene in order to confirm a potential cause and clinical diagnosis for STXBP1 Encephalopathy with epilepsy (STXBP1-E) and Ohtahara syndrome (OS).This assay is for use with human DNA extracted from peripheral blood.

Deletions or duplications detected with the P138 probemix must be confirmed by another technique. In particular, deletions or duplications detected by only a single probe always require validation by another method. Most defects in the aforementioned genes are point mutations, which will not be detected by MLPA. It is therefore recommended to use this SALSA MLPA probemix in combination with sequence analysis of these genes. This assay is not intended to be used as a standalone assay for clinical decisions. The results of this test must be interpreted by a clinical molecular geneticist or equivalent.

1Please note that this probemix is for In Vitro Diagnostic use (IVD) in the countries specified at the end of this product description. In all other countries, the product is for Research Use Only (RUO).

Clinical background: Glucose transporter type 1 (GLUT1) deficiency syndrome (GLUT1 DS; OMIM #606777) is a neurologic disorder with a broad phenotypic variability. GLUT1 DS is usually inherited in an autosomal dominant manner and in very rare cases it can occur as an autosomal recessive disease. About 10% of the autosomal dominant cases have a clinically affected parent, the remaining 90% results from a de novo heterozygous pathogenic variant. The de novo sporadic mutations may also be the result of germline mosaicism in apparently unaffected parents (Takahashi et al. 2017).

The GLUT1 DS phenotype has been reported as classic (~90%) and non-classic (~10%). The classic phenotype is characterized by infantile-onset seizures (usually between 1-6 months), delayed neurologic development, dysarthria, acquired microcephaly, and movement disorders (ataxia, dystonia, chorea). The non-classic phenotype is milder and is characterized by absence of clinical seizures, and frequent paroxysmal dyskinesias (intermittent ataxia, choreoathetosis, dystonia, alternating hemiplegia). More information is available at https://www.ncbi.nlm.nih.gov/books/NBK1430/.

STXBP1 Encephalopathy with epilepsy (STXBP1-E), also known as STXBP1 Encephalopathy or Early infantile epileptic encephalopathy-4 (EIEE4; OMIM #612164), belongs to the genetically heterogeneous group of early infantile epileptic encephalopathy (EIEE) disorders. STXBP1-E is inherited in an autosomal dominant pattern, with most of the cases being the result of a de novo mutation in the STXBP1 gene and with no history of the disorder in their family. However, these de novo sporadic mutations may also be the result of germline mosaicism in apparently unaffected parents (Saitsu et al. 2011).

STXBP1-E is characterized by recurrent seizures with early-onset (from 1 day to 13 years of age; in 94% of the cases), global development delay (90% of the cases), abnormal brain function and intellectual disability. Electroencephalography (EEG) abnormalities such as burst suppression pattern and hypsarrhythmia were reported in affected individuals. The most common type of seizures is infantile spasms, that consist of involuntary muscles spasms. Several epileptic syndromes have been linked to the STXBP1 gene, such as Ohtahara syndrome (OS; the most common syndrome, with STXBP1 defects being reported in ~20% of OS patients), West syndrome (WS), Lennox-Gastaut syndrome (LGS), Dravet syndrome (not SCN1A-related), classic Rett syndrome (not MECP2-related) and atypical Rett syndrome (not CDKL5-related). OS can develop into WS, this transition is accompanied by changes in the EEG, from suppression burst (OS) to hypsarrhythmia (WS). When progression continues to LGS it develops a generalized slow spike-wave pattern. More information is available at https://www.ncbi.nlm.nih.gov/books/NBK396561/.

Probemix content: The P138-C1 SLC2A1-STXBP1 probemix contains 43 MLPA probes with amplification products between 130 and 486 nt. It contains twelve probes for SLC2A1 and twenty-one probes for STXBP1 covering each exon of these genes. In addition, ten reference probes are included in this probemix.The identity of the genes detected by the reference probes is available online (www.mlpa.com).

This probemix contains nine quality control fragments generating amplification products between 64 and 105 nt: four DNA Quantity Fragments (Q-fragments), two DNA Denaturation Fragments (D-fragments), one benchmark fragment, and one chromosome X and one chromosome Y-specific fragment. More information on how to interpret observations on these control fragments can be found in the MLPA General Protocol and online at www.mlpa.com.

Order Items

Probemix

Item no.
Description
Technology
Price
P138-025R
SALSA MLPA Probemix P138 SLC2A1-STXBP1 – 25 rxn
€ 243.00
P138-050R
SALSA MLPA Probemix P138 SLC2A1-STXBP1 – 50 rxn
€ 486.00
P138-100R
SALSA MLPA Probemix P138 SLC2A1-STXBP1 – 100 rxn
€ 972.00

Required Reagents

Item no.
Description
Technology
Price
EK1-FAM
SALSA MLPA EK1 reagent kit – 100 rxn – FAM
€ 300.00
EK1-Cy5
SALSA MLPA EK1 reagent kit – 100 rxn – Cy5
€ 300.00
EK5-FAM
SALSA MLPA EK5 reagent kit – 500 rxn – FAM
€ 1380.00
EK5-Cy5
SALSA MLPA EK5 reagent kit – 500 rxn – Cy5
€ 1380.00
EK20-FAM
SALSA MLPA EK20 reagent kit – 2000 rxn – FAM
€ 5295.00

Related Products

SALSA MLPA Probemix P137 SCN1A

Dravet syndrome and other SCN1A-related seizure disorders; gene included: SCN1A.

SALSA MLPA Probemix P166 KCNQ2

Benign familial neonatal convulsions, contains probes for the KCNQ2 gene.

SALSA MLPA Probemix P189 CDKL5/ARX/FOXG1

Atypical Rett syndrome, X-linked infantile spasm syndrome, FOXG1 syndrome; genes included: CDKL5, NTNG1, ARX and FOXG1.

SALSA MLPA Probemix P197 KCNQ3

Familial neonatal convulsions type 2, Epilepsy benign neonatal type 2, contains probes for the KCNQ3 gene.

SALSA MLPA Probemix P330 PCDH19

Early Infantile Epileptic Encephalopathy-9 (EIEE9); gene included: PCDH19.

SALSA MLPA Probemix P408 ADLTE-LGI1

Autosomal dominant lateral temporal lobe epilepsy, contains probes for LGI1, ADAM22, GPR98, KCNA1, KCNA4, KCNAB1 and PDYN.

Sign in

Don't have an account? Create one

Forgot password?

Select Your Country

Choose your country to see the products for your location

CE

CE-marked products are for In Vitro Diagnostic (IVD) use only in EU (candidate) member states and members of the European Free Trade Association (EFTA).

IL

IVD-registered in Israel.